

**02.05.2019**

12:00 - 13:00    Type: Industry Satellite Symposium    Berlin  
Title: Industry Satellite Symposium

12:00 - 13:00    Type: Industry Satellite Symposium    Vienna  
Title: Industry Satellite Symposium

13:00 - 13:30    Type: Opening session    Exhibition area  
Title: Welcome reception

13:30 - 13:45    Type: Opening session    Maritim  
Title: Opening and welcome  
Chair(s): G. Curigliano, IT; S. Loibl, DE

13:45 - 14:15    Type: Keynote lecture    Maritim  
Title: The ESMO Breast Cancer Life Achievement Award

13:45 - 14:15    Award Lecture

14:30 - 16:00    Type: Educational session    Maritim  
Title: Early breast cancer: HER2 positive  
Chair(s): E. de Azambuja, BE; M. Untch, DE

14:30 - 14:50    Neoadjuvant therapy in ER+ positive disease  
L. Gianni, Milan, IT

14:50 - 15:10    Adjuvant therapy  
M. Piccart, Brussels, BE

15:10 - 15:30    Neoadjuvant therapy in ER-negative disease  
A. Prat, Barcelona, ES

15:30 - 15:50    Extended adjuvant therapy  
M. Martin Jimenez, Madrid, ES

15:50 - 16:00    Q&A

14:30 - 16:00 Type: Educational session Berlin  
Title: Translational oncology  
Chair(s): C. Caldas, GB

14:30 - 14:50 Molecular heterogeneity of breast cancer  
C. Caldas, Cambridge, Cambridgeshire/GB

14:50 - 15:10 Modelling breast cancer using patient-derived models

15:10 - 15:30 Modelling breast cancer using GEMMs  
M. Bentires-Aj, Basel, CH

15:30 - 15:50 Developing targeted breast cancer therapies  
L. Friedman, South San Francisco, US

15:50 - 16:00 Q&A

14:30 - 16:00 Type: Proffered Paper session Vienna  
Title: Proffered Paper session

16:00 - 16:30 Type: Coffee break Exhibition area  
Title: Coffee break

16:30 - 18:00 Type: Educational session Maritim  
Title: Early breast cancer: HER2-/HR positive  
Chair(s): M. Ellis, US

16:30 - 16:50 Neoadjuvant endocrine therapy, when and why?  
M. Ellis, Houston, TX/US

16:50 - 17:10 Genomics of intrinsic endocrine resistance, new insights and therapeutic hypotheses

17:10 - 17:30 Late relapse and duration of therapy, where are we?  
M. Dowsett, London, GB

17:30 - 17:50 Ovarian suppression, whom, which agents, how long, and at what cost?  
O. Pagani, Bellinzona, CH

17:50 - 18:00 Q&A

16:30 - 18:00    Type: Educational session    Berlin  
 Title: Selection of high risk /low risk patients  
 Chair(s): C. Sotiriou, BE

16:30 - 16:50    Gene profiling for risk assessment: Are they still useful?  
C. Sotiriou, Brussels, BE

16:50 - 17:10    Circulating tumour markers (CTC- ctDNA- exosomes): Toward the holy grail for risk assessment?  
M. Ignatiadis, Brussels, BE

17:10 - 17:30    Life style factors: Any influence on the risk?  
P. Goodwin, Toronto, Ontario/CA

17:30 - 17:50    Is there any biomarker to assess late relapse?  
I. Sestak, London, GB

17:50 - 18:00    Q&A

16:30 - 18:00    Type: Poster Discussion session    Vienna  
 Title: Poster Discussion session

18:30 - 19:30    Type: Industry Satellite Symposium    Berlin  
 Title: Industry Satellite Symposium

18:30 - 19:30    Type: Industry Satellite Symposium    Vienna  
 Title: Industry Satellite Symposium

18:30 - 19:30    Type: Industry Satellite Symposium    Riga  
 Title: Industry Satellite Symposium

**03.05.2019**

07:45 - 08:30    Type: Special session    Berlin  
 Title: To be announced

07:45 - 08:30    Type: Young Oncologist session    Riga  
 Title: Meet the Professor

08:30 - 09:30 Type: Controversy session Vienna  
Title: Platinum agents in the neoadjuvant setting for TNBC  
Chair(s): M. Ellis, US

08:30 - 08:40 Introduction and first vote

08:40 - 09:00 Pro  
S. Verma, Calgary, Alberta/CA

09:00 - 09:20 Contra  
S. Delaloge, Villejuif, FR

09:20 - 09:30 Second vote and conclusions

08:45 - 10:15 Type: Educational session Maritim  
Title: Early breast cancer: TNBC  
Chair(s): M. Martin Jimenez, ES

08:45 - 09:05 TNBC: Are all tumors equal? The pathologists view  
C. Denkert, Berlin, DE

09:05 - 09:25 Prognosis factors of early TNBC patients  
S. Loi, Melbourne, VIC/AU

09:25 - 09:45 Neo/Adjuvant therapy of early TNBC  
S. Loibl, Neu-Isenburg, DE

09:45 - 10:05 Management of early TNBC in BRCA 1-2 mutation carriers

10:05 - 10:15 Q&A

08:45 - 10:15 Type: Proffered Paper session Berlin  
Title: Proffered Paper session

09:45 - 10:15	Type: Spotlight Title: Spotlight on prevention and epidemiology	Vienna
09:45 - 10:05	Spotlight on prevention and epidemiology <u>S. Paluch-Shimon</u> , Jerusalem, IL	
10:05 - 10:15	Discussion	
10:15 - 10:45	Type: Coffee break Title: Coffee break	Exhibition area
10:45 - 12:15	Type: Educational session Title: Immune oncology Chair(s): S. Loi, AU	Maritim
10:45 - 11:05	Update of current clinical data of checkpoint inhibition in breast cancer <u>M.V. Dieci</u> , Padova, IT	
11:05 - 11:25	Markers of response and resistance to PD-1; PD-L1 inhibition in solid tumour types - lessons for breast cancer <u>B. Seliger</u> , Halle, DE	
11:25 - 11:45	T cells - are they really exhausted- and relevance to breast cancer	
11:45 - 12:05	Monitoring the immune system- new and old technologies and their clinical implications <u>R. Salgado</u> , Wilrijk, BE	
12:05 - 12:15	Q&A	

10:45 - 12:15    Type: Educational session    Berlin  
Title: Personalised medicine  
Chair(s): F. André, FR

10:45 - 11:05    What did we learn from the sequencing of metastatic breast cancers?

11:05 - 11:25    Use of multigene panels for metastatic breast cancers

11:25 - 11:45    Rare genomic entities in metastatic breast cancers

11:45 - 12:05    Trial methodology in precision medicine  
S. Michiels, Villejuif, FR

12:05 - 12:15    Q&A

10:45 - 12:15    Type: Educational session    Vienna  
Title: Metastatic breast cancer: HER2 positive  
Chair(s): J. Cortes Castan, ES

10:45 - 11:05    Understanding antiHER2 mechanisms of resistance  
J. Albanell, Barcelona, ES

11:05 - 11:25    Moving into the future understanding the present  
A. Awada, Brussels, BE

11:25 - 11:45    How to treat brain metastases?  
R. Bartsch, Vienna, AT

11:45 - 12:05    The role of immunotherapy in HER2+ metastatic breast cancer  
E. de Azambuja, Brussels, BE

12:05 - 12:15    Q&A

10:45 - 12:15	Type: Special session Title: Breast cancer in young women: From guidelines to clinical practice	Riga
10:45 - 11:05	The biology of breast cancer in young women: What is different <u>A. Partridge</u> , Boston, US	
11:05 - 11:25	ESO-ESMO BCY Guidelines: Optimal management of young women with breast cancer <u>O. Pagani</u> , Bellinzona, CH	
11:25 - 11:45	Fertility preservation and pregnancy after the disease	
11:45 - 12:00	Survivorship issues <u>S. Paluch-Shimon</u> , Jerusalem, IL	
12:00 - 12:15	Research priorities <u>F. Cardoso</u> , Lisbon, PT	
12:15 - 13:00	Type: Poster display session Title: Poster lunch	Exhibition area
13:00 - 14:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Berlin
13:00 - 14:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Vienna
13:00 - 14:00	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Riga
14:10 - 14:40	Type: Keynote lecture Title: Keynote lecture: Hereditary breast cancer and PARP inhibitors Chair(s): <u>A. Tutt</u> , GB	Maritim
14:10 - 14:40	Hereditary breast cancer and PARP inhibitors <u>M. Robson</u> , New York, US	

14:45 - 16:15	Type: Multidisciplinary tumour board Title: Premenopausal women with early ER+/HER2 negative breast cancer and metastatic breast cancer Chair(s): H. Burstein, US; P.F. Conte, IT	Maritim
14:45 - 15:05	Metastatic breast cancer from a medical oncology perspective <u>P.F. Conte</u> , Padova, IT	
15:05 - 15:25	Early breast cancer from a medical oncology perspective <u>H. Burstein</u> , Boston, US	
15:25 - 15:45	Radio-oncology perspective <u>P. Poortmans</u> , Paris, FR	
15:45 - 16:05	Surgery perspective	
16:05 - 16:15	Q&A	
16:15 - 16:45	Type: Coffee break Title: Coffee break	Exhibition area
16:45 - 18:15	Type: Proffered Paper session Title: Best abstracts session	Maritim
18:30 - 19:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Berlin
18:30 - 19:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Vienna
18:30 - 19:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Riga
<b>04.05.2019</b>		
07:45 - 08:30	Type: Special session Title: To be announced	Berlin
07:45 - 08:30	Type: Young Oncologist session Title: Meet the Professor	Riga



08:30 - 09:30	Type: Controversy session Title: Multigene testing for treatment decision in early and metastatic breast cancer Chair(s): F. André, FR	Vienna
08:30 - 08:40	Introduction and first vote	
08:40 - 09:00	Pro <u>J. Bergh</u> , Stockholm, Solna/SE	
09:00 - 09:20	Contra <u>V. Guarneri</u> , Padova, IT	
09:20 - 09:30	Second vote and conclusions	
08:45 - 10:15	Type: Educational session Title: Metastatic breast cancer: HER2-/HR positive Chair(s): F. Cardoso, PT; N. Turner, GB	Maritim
08:45 - 09:05	Advances in targeting the estrogen receptor <u>S. Johnston</u> , London, GB	
09:05 - 09:25	Resistance to CDK4/6 inhibitors: Clinical implications <u>N. Turner</u> , London, GB	
09:25 - 09:45	Sequencing of targeted therapies for the individual patient <u>F. Cardoso</u> , Lisbon, PT	
09:45 - 10:05	When chemotherapy is required <u>N. Harbeck</u> , Munich, DE	
10:05 - 10:15	Q&A	
08:45 - 10:15	Type: Poster Discussion session Title: Poster Discussion session	Berlin

09:45 - 10:15	Type: Spotlight Title: Spotlight on breast cancer survivorship	Vienna
09:45 - 10:05	Spotlight on breast cancer survivorship <u>I. Vaz-Luis</u> , Villejuif, FR	
10:05 - 10:15	Discussion	
10:15 - 10:45	Type: Coffee break Title: Coffee break	Exhibition area
10:45 - 12:15	Type: Educational session Title: Metastatic breast cancer: TNBC Chair(s): A. Eniu, RO; V. Dieras, FR	Maritim
10:45 - 11:05	Understanding the biology of TNBC: Where are we in 2019? <u>J. Reis-Filho</u> , New York, NY/US	
11:05 - 11:25	Harnessing the immune response in TNBC: Are we mastering it? <u>P. Schmid</u> , London, GB	
11:25 - 11:45	Who does NOT need PARP inhibition? <u>G. Curigliano</u> , Milan, IT	
11:45 - 12:05	Is chemotherapy becoming obsolete in TNBC? <u>A. Eniu</u> , Cluj-Napoca, RO	
12:05 - 12:15	Q&A	

10:45 - 12:15 Type: Educational session Berlin  
 Title: Radiation therapy  
 Chair(s): W. Budach, DE; P. Poortmans, FR

10:45 - 11:05 Current challenges  
W. Budach, Düsseldorf, DE

11:05 - 11:25 Individualised target volume selection and dose prescription  
P. Poortmans, Paris, FR

11:25 - 11:45 Current technical solutions for clinical worries  
M. Algara, Barcelona, ES

11:45 - 12:05 Can we do even better: Future options  
J.H. Maduro, Groningen, NL

12:05 - 12:15 Q&A

10:45 - 12:15 Type: Educational session Vienna  
 Title: Innovative treatment across subtypes  
 Chair(s): L. Pusztai, US; N. Harbeck, DE

10:45 - 11:05 Changing paradigms in sequencing of treatment modalities in early stage breast cancer  
N. Harbeck, Munich, DE

11:05 - 11:25 The role of metastatic tumor profiling and targeted therapies  
L. Pusztai, Houston, TX/US

11:25 - 11:45 Emerging role of antibody-drug conjugates  
A. di Leo, Prato, PO/IT

11:45 - 12:05 Immune therapy as a generalistic approach  
M. Kok, Amsterdam, NL

12:05 - 12:15 Q&A

10:45 - 12:15	Type: Special session Title: The changing paradigm for breast cancer surgery Chair(s): T. Kovacs, GB; F. Cardoso, PT	Riga
10:45 - 10:50	Introduction <u>T. Kovacs</u> , London, GB	
10:50 - 11:10	Observation of DCIS	
11:10 - 11:30	Sentinel lymph node biopsy after neoadjuvant therapy: Where do we go from there? <u>I. Rubio</u> , Barcelona, ES	
11:30 - 11:50	Oncoplastic breast conservative surgery for multicentric tumors: No more exclusion criteria for clinical trials <u>T. Kovacs</u> , London, GB	
11:50 - 12:10	Do all BRCA carriers with breast cancer benefit from bilateral mastectomy? <u>R. Ponzzone</u> , Candiolo, IT	
12:10 - 12:15	Conclusions <u>F. Cardoso</u> , Lisbon, PT	
12:30 - 13:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Vienna
12:30 - 13:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Riga